Last reviewed · How we verify
Clindamycin Phosphate RLD
Clindamycin Phosphate RLD is a Lincosamide antibiotic Small molecule drug developed by Sun Pharmaceutical Industries, Inc.. It is currently in Phase 1 development. Also known as: Lotion.
Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Clindamycin Phosphate RLD is a small molecule that inhibits the bacterial 70S ribosome. It is used to treat Acne Vulgaris, as demonstrated in a randomized, double-blind, multiple center placebo controlled study.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Clindamycin Phosphate RLD |
|---|---|
| Also known as | Lotion |
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Drug class | Lincosamide antibiotic |
| Modality | Small molecule |
| Phase | Phase 1 |
Mechanism of action
Clindamycin binds to the 23S RNA of the 50S ribosomal subunit, blocking the transpeptidation or translocation reactions, thereby inhibiting early chain elongation. This bacteriostatic action prevents bacterial growth and replication in susceptible organisms.
Approved indications
Common side effects
Key clinical trials
- Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris (PHASE1)
- Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clindamycin Phosphate RLD CI brief — competitive landscape report
- Clindamycin Phosphate RLD updates RSS · CI watch RSS
- Sun Pharmaceutical Industries, Inc. portfolio CI
Frequently asked questions about Clindamycin Phosphate RLD
What is Clindamycin Phosphate RLD?
How does Clindamycin Phosphate RLD work?
Who makes Clindamycin Phosphate RLD?
Is Clindamycin Phosphate RLD also known as anything else?
What drug class is Clindamycin Phosphate RLD in?
What development phase is Clindamycin Phosphate RLD in?
Related
- Drug class: All Lincosamide antibiotic drugs
- Manufacturer: Sun Pharmaceutical Industries, Inc. — full pipeline
- Also known as: Lotion
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing